Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

SA Transcripts159.1K FollowersFollow5ShareSaveCommentsQ4: 2026-03-23 Earnings SummaryPlay CallPlay Call10-KEPS of -$0.06 beats by $0.02 | Revenue of $0.00 beats by $0.00 Talphera, Inc. (TLPH) Analyst/Investor Day March 23, 2026 11:00 AM EDT Company Participants Vincent Angotti - CEO & DirectorShakil Aslam - Chief Medical Officer Conference Call Participants Joao TeixeiraBlaithin McMahonNazibur Rahman - Maxim Group LLC, Research DivisionYuan Zhi - B. Riley Securities, Inc., Research DivisionAntonio Arce - WestPark Capital, Inc.James Molloy - Alliance Global Partners, Research Division Presentation Operator Good morning, everyone, and welcome to the Talphera Virtual Analyst and Investor event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be made available on the Talphera website following the conclusion of the event. I'd now like to turn the call over to Vince Angotti, Chief Executive Officer at Talphera. Please go ahead. Vincent AngottiCEO & Director Thank you, Tara. And good morning, everyone, and thank you for joining our event today. I'm excited to be joined by Dr. Shakil Aslam, Talphera's Chief Medical Officer; and 2 key experts in continuous renal replacement therapy who are also principal investigators in our NEPHRO CRRT registrational study. To their experience and expertise, we hope to provide you with a better understanding of CRRT, the anticoagulants currently being used during CRRT and how these experts see nafamostat potentially filling an unmet need for anticoagulation of the CRRT circuit. Our agenda will specifically include, first, a very brief business update, so we can move quickly to our key expert discussion, followed by Q&A and closing remarks. Before we begin, I want to remind listeners that during this call, we'll likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Talphera. Please refer to our press release in addition to the company's periodic, current and annual reports filed with the SEC for a discussion of the risks associated with such forward-looking